AMG 386 + pemetrexed + carboplatin

AMG 386 + pemetrexed + carboplatin is an investigational three-drug combination regimen evaluated in the treatment of solid tumors, particularly non-small cell lung cancer and malignant pleural mesothelioma. **AMG-386 (trebananib)** is a recombinant fusion peptibody that selectively binds and neutralizes angiopoietin-1 and angiopoietin-2, preventing their interaction with the Tie-2 receptor and inhibiting angiogenesis, a key process in tumor growth and progression[1][5][7]. **Pemetrexed** is a folate antimetabolite that disrupts folate-dependent metabolic processes essential for cell replication, used as chemotherapy for NSCLC and mesothelioma[8]. **Carboplatin** is a platinum-based agent that causes DNA crosslinking, leading to apoptosis in rapidly dividing cancer cells. The combination is typically given intravenously, is under investigation in advanced solid tumors, and has demonstrated anti-tumor activity and tolerability in preclinical and early clinical studies[1][2][4][6][8].

Other names

trebananibAMG-386AMG386AMG 386carboplatinpemetrexed